Anita Nelsen has more than 20 years of experience in the pharmaceutical industry and 29 years of experience in pharmacogenetic, human and molecular genetics research in roles including bench scientist, manager and function leader. At PAREXEL, she leads a global team of scientists who are recognized thought leaders and influencers in quantitative clinical pharmacology, modeling and simulation, biomarkers and genomic-based drug development to help clients strategically leverage and seamlessly integrate technologies across all phases of development. Read her full bio.

Interview with Anita Nelsen of PAREXEL

Q: There are various new, emerging technologies that bring us closer towards a cure for life-threatening disorders such as cancer, HIV, or Huntington’s disease. Prominent examples include the popular gene editing tool CRISPR or new and improved cell and gene therapies. By when can we expect these new technologies being part of routine clinical care?

A: Today’s emerging technologies are making the promise of individualized treatment a reality. We are able to edit genes, customize treatments down to a molecular level, and more. These technologies are exciting and hold a lot of potential, but they must be brought to clinical care in a compliant manner with well-designed and ethical clinical trials that showcase patient outcomes. With this testing, there is also a need for education so providers and consumers understand the impact and power of the technology, choose to participate in the clinical trials, and ultimately make informed treatment decisions.

Many precision medicine clinical trials, including those that leverage cell and gene therapies, are in early phases, so even with emerging and new regulatory guidance and pathways, it will likely take some time for these types of treatments to become mainstream for clinical care. Further, pathways to reimbursement also need to be established for these novel therapies. That said, these types of trials are promising – recent research conducted by The Economist Intelligence Unit (EIU) and commissioned by PAREXEL found that drugs developed using precision medicine trials were 10 percentage points more likely to be launched.

Q: What other emerging technologies will have a significant impact on patient care in the near and far future?

A: In the near and far future, we see patient data and analytics continuing to have a significant impact on care. The information, quality and consistency of it and how it’s analyzed are the keys to unlocking true precision medicine where patients receive customized treatments based on their genetic makeup, lifestyle, and other factors. Although patient data has been available for some time, the types of data we are accessing are getting more complex. In the future physicians may need to consider an individual’s genome, their immune biomarkers, and even their microbiome when helping to assess treatment options or recommend lifestyle changes. Not only are we collecting new types of data but there are still new ways to track it (e.g. wearables and sensors, smartphones, direct to consumer tests); however, there are challenges to understanding, aggregating and analyzing the quality of this data. If successful, the data holds the potential of providing powerful new algorithms and machine learning to predict outcomes and uncover new treatment avenues.

Additionally, we continue to see growth in adoption of patient-centric trials, which are designed specifically around patients’ needs to make it as easy and as convenient as possible to participate in research. There is more direct involvement of patients and/or their caregivers and/or patient advocacy groups in the initial design of studies. We’re also seeing increasing use of technology, such as wearable sensors, to enable the capture of clinical data in the home setting.

These advances are likely to improve the delivery of new drugs to market. Recent research findings from the EIU showed that patient-centric trials enrolled patients faster and are more likely to succeed, taking an average of four months to enroll 100 patients in patient-centric trials versus seven months for non-patient-centric trials. These types of trials also had a higher probability of success progressing from Phase II and III to market launch.

Q: In order to maximize the potential of the aforementioned technologies in the clinic, what strategies need to be adapted?

A: There are three main things that need to happen to maximize the potential of these technologies and ultimately precision medicines in the clinic.

  • First, payers need to cover these medicines. To do so, they need new and different models to assess these therapies versus therapies developed via traditional drug development paradigms.  They must understand the target patient profile, potential benefits, and risk of harm associated with these novel approaches as well as the cost impacts. Some have suggested that models for reimbursement need to be more innovative and there may be cause for risk-sharing models with pharma sponsors. Real world data and advanced analytics will likely play a critical role in these helping pharma convince payers of that targeted patient groups that are most likely to benefit from precision medicines and therapies.
  • Second, in the clinic, healthcare providers (HCPs) need to be equipped to analyze and interpret the data and translate it into treatment decisions that lead to better patient outcomes. They need the tools and infrastructure to obtain, analyze, and translate the data into treatment decisions.  At some level, they need to understand the data science and technology.
  • Finally, we need to translate the information to the patient in a way that is understandable and contributes to patients making informed decisions about testing, treatment, and lifestyle.
Q: What are some of the major challenges that need to be overcome before we can see widespread applications across the clinic?

A: Data and information sharing are major challenges that many in the industry are currently working to overcome. We have seen many potential solutions such as electronic health records, patient wearables, etc. to gather and share data but there are still roadblocks ahead. It’s going to take continual out-of-the-box thinking and communication to ensure that providers, trialists, and other industry stakeholders have the full picture of the data, how it better helps us understand diseases, and how to treat them.

Another challenge that has surfaced with the rise of precision medicine: human sample management. With an increased amount of these trials, scientists need certain biological resources to support discovery and development of precision medicine therapies, making biobanking and exploratory analyses a routine part of research. However, there are perceived challenges that come along with biobanking in global clinical trials, such as varied regulations and cultural perceptions, concerns about cost, potential delays in clinical trial recruitment and conduct, and ownership of and access to data and privacy risks for participants. All of these can be overcome but they are real challenges.

Q: How can and should the community work together to get those various technologies safely into the clinic?

A: Working together is critical and more and more I think the precision medicine community is working together. It takes a long time to drive culture change necessary to move from traditional, highly secretive drug development models to collaborative or cooperative models where data sharing fuels understanding of disease and identification of new drug targets to companies that work collaboratively to execute novel trial designs that can assess the efficacy of multiple drugs in parallel or develop a diagnostic test to use with multiple medicines. Early engagement with regulators and payers is encouraged and even expected to help pave the way for smooth review. We have finally realized that we all face the same challenges—having the tools and experience to make sense of the complicated new data types and drive decisions. We can solve for these challenges more efficiently if we work as a team.

Q: What solution is your organization providing to address what need in precision medicine?

A: PAREXEL is working closely with sponsors to implement innovative clinical trial designs leveraging these emerging technologies. Our experts are partnering with clients across the drug and diagnostic development continuum to design and implement biomarker and genomic strategies that support their assets from pre-clinical to post-market. Our precision medicine experts provide commercial, regulatory, medical, and scientific consultation to help sponsors understand the therapeutic and commercial benefit to leveraging diagnostic tools to make sure the right patients receive the right treatments at the right time. The Company is also hosting a series of closed session workshops with experts across the healthcare industry to identify barriers as well as enablers of adoption that can improve the future of drug development, related to precision medicine and other innovations.

Q: Is there anything you would like to share with the PMWC audience?

A: As a community, we have worked hard to demonstrate the value proposition of precision medicine strategies. As recognition of this value increases we must now demonstrate that we can overcome the challenges that come with the approach, and that we can build the experienced workforce, the data analytic technologies, and the collaborative partnerships to move from development to treatment and potentially cures.

Interview with Gabriel Bien-Willner of Palmetto GBA

Q: What does your role entail as the director of the MolDX program at Palmetto GBA?

A: The job directing MolDX is multifaceted; first and foremost the MolDX program is responsible for assessing molecular diagnostic tests on the market and makes coverage and pricing determinations for such tests and technology. This is usually done through local coverage determination policies or technical assessments.

Read More

Interview with Peter Marks of FDA

Q: The CBER’s Regenerative Medicine Advanced Therapy Designation program has been very successful, with about 100 requests for designation in the two years of its existence. Can you please tell us about the program and how it was put together?

A: The Regenerative Medicine Advanced Therapy (RMAT) Designation program came into being as part of the 21st Century Cures Act that was signed into law on December 13, 2016.

Read More

Interview with Calum MacRae of Harvard Medical School

Q: What patient data do we need to better understand the underlying cause of disease and how to prevent it?

A: Medicine at present is highly underdetermined and data poor. To be precise, one must be comprehensive, so medicine (with our consent) will use not only what we currently conceive of as biomedical information, but also data from across our lives.

Read More

Headlines from PMWC 2019 Silicon Valley

A big ‘Thank You’ to all of our presenters and attendees for celebrating 10 years of precision medicine progress with us! PMWC 2019 Silicon Valley was attended by 2000 participants from 35 countries, which included over 400 speakers in 5 parallel tracks!

Read More

Interview with Ken Bloom of Ambry Genetics

Q: Tell us more about your organization/company. What patient population are you serving and which services are you specializing in?

A: Ambry Genetics is a recognized leader in high quality complex genetic testing. We seek to find the genomic cause or contributors to rare diseases, abnormal phenotypes and hereditary disorders.

Read More

Interview with Lee Pierce of Sirius Computer Solutions

Q: What is the state of big data and analytics in healthcare, and how to best use the reams of data available?

A: More than ever, Healthcare organizations are achieving measurable value through use of their data and analytics assets. There is more raw material available than ever to create value. This raw material is the data flowing from internal systems and applications and also from devices and systems external to healthcare organizations.

Read More

Interview with Anita Nelsen of PAREXEL

Q: There are various new, emerging technologies that bring us closer towards a cure for life-threatening disorders such as cancer, HIV, or Huntington’s disease. Prominent examples include the popular gene editing tool CRISPR or new and improved cell and gene therapies. By when can we expect these new technologies being part of routine clinical care?

A: Today’s emerging technologies are making the promise of individualized treatment a reality.

Read More

Interview with Ilan Kirsch of Adaptive Biotechnologies

Q: The Nobel Prize in Medicine was awarded recently to James Allison and Tasuku Honjo for their work on unleashing the body’s immune system to attack cancer, a breakthrough that has led to an entirely new class of drugs and brought lasting remissions to many patients who had run out of options. The Nobel committee hailed their accomplishments as establishing “an entirely new principle for cancer therapy.” What is your first-hand experience the impact that those new drugs had on patients?

A: For decades cancer was viewed as solely a cell-autonomous condition.

Read More

BMS buys Celgene | Lilly buys Loxo Oncology – Does this Signal a Return to Strong Deal-Making Activities in 2019?

Bristol-Myers Squibb’s blockbuster $74B deal to buy Celgene creates an oncology powerhouse amid industrywide excitement about the rapidly evolving science and explosive growth of the sector. The agreement could signal a return to deal-making for the pharmaceutical industry in the $133B global oncology therapeutics market.

Read More

Interview with Gini Deshpande of NuMedii

Q: What need is NuMedii addressing?

A: NuMedii, has been pioneering the use of Big Data, artificial intelligence (AI) and systems biology since 2010 to accelerate the discovery of precision therapies to address high unmet medical needs. Artificial Intelligence approaches are a natural fit to harness Big Data as they provide a framework to ‘train’ computers to recognize patterns and sift through vast amounts of new and existing genomic

Read More

Interview with Minnie Sarwal of UCSF

Q: Genomic medicine is entering more hospitals and bringing with it non-invasive technology that can be used to better target and treat diseases. What are some key milestones that contributed to this trend?

A: Completion of complete sequence data from the human genome project, and the advances in proteomic, microRNA and epigenetic assays added a layer of pathway biology to the understanding of human diseases.

Read More

Interview with Shidong Jia of Predicine

Q: Once sequencing has been validated as a clinical solution via trusted workflows, and coinciding with the technological developments driving costs lower, we can expect accelerated human genome profiling for clinical Dx. How soon, do you think, will we see accelerated growth and what can we expect?

A: We will see accelerated human genome profiling for clinical Dx in 2019 and the coming years as more biomarker-based cancer drugs are gaining approval.

Read More

Interview with Iya Khalil of GNS Healthcare

Q: Artificial intelligence (AI) techniques have sent vast waves across healthcare, even fueling an active discussion of whether AI doctors will eventually replace human physicians in the future. Do you believe that human physicians will be replaced by machines in the foreseeable future? What are your thoughts?

A: I think that there’s a lot of speculation and uncertainty around AI, but I don’t foresee a time when we won’t need physicians.

Read More

Interview with Ilya Michael Rachman of Immix Biopharma Inc.

Q: The Nobel Price in Medicine was awarded recently to James Allison and Tasuku for their work on unleashing the body’s immune system to attack cancer, a breakthrough that has led to an entirely new class of drugs and brought lasting remissions to many patients who had run out of options. The Nobel committee hailed their accomplishments as establishing “an entirely new principle for cancer therapy.” Besides CAR T-cell therapy what do you think next generation immunotherapies will look like to successfully combat cancer?

A: The next generation of immunotherapies will build on the insights discovered by immunologists like James Allison and Tasuku Honjo and extend them to modify the body’s response to tumors.

Read More

Join me to Kick off PMWC Silicon Valley in the Santa Clara Convention Center, Focusing on Every Element of Precision Medicine

My team worked in collaboration with Bill Dalton, Kim Blackwell, Atul Butte / India Hook Barnard, Nancy Davidson and Sharon Terry to create a program that touches every component of precision medicine while bringing together all of its key stakeholders. Leading participating institutions including Stanford Health Care, UCSF, Duke Health, Duke University, John Hopkins University, University of Michigan and more will share their learnings and experiences and their successes and challenges, as they make precision medicine the new standard of care for all.

Read More
Johns Hopkins
University Of Michigan

The Precision Medicine World Conference (PMWC), in its 17th installment, will take place in the Santa Clara Convention Center (Silicon Valley) on January 21-24, 2020. The program will traverse innovative technologies, thriving initiatives, and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advancements in precision medicine and cutting-edge new strategies and solutions that are changing how patients are treated.

See 2019 Agenda highlights:

  • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • AI & Data Science Showcase
    • Clinical & Research Tools Showcase
    • Clinical Dx Showcase
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Digital Health/Health and Wellness
    • Digital Phenotyping
    • Diversity in Precision Medicine
    • Drug Development (PPPs)
    • Early Days of Life Sequencing
    • Emerging Technologies in PM
    • Emerging Therapeutic Showcase
    • FDA Efforts to Accelerate PM
    • Gene Editing
    • Genomic Profiling Showcase
    • Immunotherapy Sessions & Showcase
    • Implementation into Health Care Delivery
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Microbial Profiling Showcase
    • Microbiome
    • Neoantigens
    • Next-Gen. Workforce of PM
    • Non-Clinical Services Showcase
    • Pharmacogenomics
    • Point-of Care Dx Platform
    • Precision Public Health
    • Rare Disease Diagnosis
    • Resilience
    • Robust Clinical Decision Support Tools
    • Wellness and Aging Showcase

See 2019 Agenda highlights:

    • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • AI & Data Science Showcase
      • Clinical & Research Tools Showcase
      • Clinical Dx Showcase
      • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
      • Digital Health/Health and Wellness
      • Digital Phenotyping
      • Diversity in Precision Medicine
      • Drug Development (PPPs)
      • Early Days of Life Sequencing
      • Emerging Technologies in PM
      • Emerging Therapeutic Showcase
      • FDA Efforts to Accelerate PM
      • Gene Editing / CRISPR
      • Genomic Profiling Showcase
      • Immunotherapy Sessions & Showcase
      • Implementation into Health Care Delivery
      • Large Scale Bio-data Resources to Support Drug Development (PPPs)
      • Microbial Profiling Showcase
      • Microbiome
      • Neoantigens
      • Next-Gen. Workforce of PM
      • Non-Clinical Services Showcase
      • Pharmacogenomics
      • Point-of Care Dx Platform
      • Precision Public Health
      • Rare Disease Diagnosis
      • Resilience
      • Robust Clinical Decision Support Tools
      • Wellness and Aging Showcase
  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 2000+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine
Get Updates
Sign up for occasional updates on upcoming conferences, news, and other information.
We respect your privacy and will never share your email with anyone.
Something went wrong, please verify your input.
Thank you for signing up!

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

View the top 3 talks from PMWC here (password: top-videos).